Filing Flows › Companies › ARS Pharmaceuticals › Report card
ARS Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate1 of 5 reports beat the EPS estimate
ARS Pharmaceuticals (SPRY) beat the analysts' EPS estimate in 1 of its last 5 reports (20%), by -8.7% on average.
Beat rate20% of 5
Average surprise-8.7%
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | −$0.33 | −$0.36 | -8.0% | $37.7M |
| Q2 2026 | Aug 13, 2026 | −$0.49 | −$0.63 | -27.7% | $33.7M |
| Q1 2026 | May 15, 2026 | −$0.54 | −$0.61 | -14.0% | $22.7M |
| Q4 2025 | Mar 9, 2026 | −$0.48 | −$0.42 | +12.5% | $28.1M |
| Q3 2025 | Nov 10, 2025 | −$0.49 | −$0.52 | -6.1% | $32.5M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → ARS Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.